Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Rentokil shares jump 12% as North America growth lifts 2025 results (Investing.com) +++ RENTOKIL Aktie +4,08%

ELEKTA Aktie

 >ELEKTA Aktienkurs 
5.485 EUR    +1.4%    (TradegateBSX)
Ask: 5.78 EUR / 2600 Stück
Bid: 5.73 EUR / 2700 Stück
Tagesumsatz: 7600 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ELEKTA Aktie über LYNX handeln
>ELEKTA Performance
1 Woche: +1,6%
1 Monat: +4,9%
3 Monate: +6,2%
6 Monate: +32,2%
1 Jahr: +1,0%
laufendes Jahr: +2,6%
>ELEKTA Aktie
Name:  ELEKTA AB B SK 2
Land:  Schweden
Sektor:  Gesundheit
ISIN/ Wkn:  SE0000163628 / 896279
Symbol/ Ticker:  EJXB (Frankfurt)
Kürzel:  FRA:EJXB, ETR:EJXB, EJXB:GR
Index:  -
Webseite:  http://www.elekta.com/
Profil:  Elekta AB (publ) is a Swedish public limited liability company specializing in the development and production of precision radiation therapy and radiosurgery equipment for treating cancer and brain di..
>Volltext..
Marktkapitalisierung:  2041.86 Mio. EUR
Unternehmenswert:  2506.44 Mio. EUR
Umsatz:  1589.35 Mio. EUR
EBITDA:  244.37 Mio. EUR
Nettogewinn:  26.33 Mio. EUR
Gewinn je Aktie:  0.07 EUR
Schulden:  687.78 Mio. EUR
Liquide Mittel:  233.06 Mio. EUR
Operativer Cashflow:  290.78 Mio. EUR
Bargeldquote:  0.21
Umsatzwachstum:  4.88%
Gewinnwachstum:  -69.3%
Dividende je Aktie:  0.22 EUR
Dividendenrendite:  4.2%
Dividendenschätzung:  4.2%
Div. Historie:  05.09.25 - 0.108456€
06.03.25 - 0.108456€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  ELEKTA
Letzte Datenerhebung:  05.03.26
>ELEKTA Kennzahlen
Aktien/ Unternehmen:
Aktien: 367.1 Mio. St.
Frei handelbar: 97.99%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 4556
Umsatz/Mitarb.: 0.35 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 8.65%
Bewertung:
KGV: 73.26
KGV lG: 17.7
KUV: 1.22
KBV: 2.53
PEG-Ratio: -
EV/EBITDA: 10.26
Rentabilität:
Bruttomarge: 37.96%
Gewinnmarge: 1.66%
Operative Marge: 12.03%
Managementeffizenz:
Gesamtkaprendite: 0.96%
Eigenkaprendite: 3.08%
>ELEKTA Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
05.03.26 - 10:31
Elekta Q3-Ergebnisse: Organisches Wachstum von 2 % trotzt Währungsgegenwind (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.03.26 - 09:33
Elekta Q3 net profit slumps as FX, restructuring charge hit earnings (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
26.02.26 - 08:18
Tomas Puusepp appointed Chair of the Board at Permobil (Cision)
 
Tomas Puusepp, professional board member and former CEO of Elekta, has been appointed new Chair of the Board at Permobil. Puusepp, who has served on Permobil's Board for almost 10 years, will assume the role in June, succeeding Martin Lundstedt, who has chaired the Board since 2013, when Investor acquired Permobil. “I am very pleased to welcome Tomas Puusepp as Permobil's new Chair and look forward to continuing to work together in this new role. His experience and long-standing commitment to the company will be invaluable as Permobil continues its growth journey. I would also like to...
19.01.26 - 20:30
Elekta Wins FDA Nod for Evo CT-Linac, Boosting U.S. Radiation Oncology (Zacks)
 
EKTAY jumps after FDA clears Evo CT-Linac, opening U.S. access to AI-driven CT imaging that boosts precision and efficiency in radiation therapy....
07.01.26 - 14:36
Sensus Healthcare Appoints Larry Biscotti to its Board of Directors (Business Wire)
 
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologies. He currently serves as President, Imaging for the U.S. and Canada at GE HealthCare, where he is responsible for the company's largest global product and solutions segment. His prior work history includes positions with Elekta, Varian Medical Systems, Toshiba Medical, SMV Nuclear Me...
26.11.25 - 14:09
Elekta AB reports Q2 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.11.25 - 13:27
Elekta AB Non-GAAP EPS of SEK 0.64, revenue of SEK 4.07B; reaffirms FY outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.11.25 - 09:48
Elekta shares jump 11% after Q2 margin beat despite weak orders (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.09.25 - 21:09
XFRA: DIVIDEND/INTEREST INFORMATION - 05.09.2025 - SE0000163628 (XETRA)
 
Das Instrument EJXB SE0000163628 ELEKTA AB B SK 2 EQUITY wird ex Dividende/Zinsen gehandelt am 05.09.2025 The instrument EJXB SE0000163628 ELEKTA AB B SK 2 EQUITY has its ex-dividend/interest day on 05.09.2025...
03.09.25 - 14:01
UBS initiates Elekta at “sell,” cites slowing radiotherapy market and 30% downside (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
29.08.25 - 11:06
Johan Andersson appointed new head of Investor Relations (Cision)
 
Saab has appointed Johan Andersson as the new head of Investor Relations. He will assume his position on September 15, 2025. Johan Andersson has more than 15 years of experience in investor relations and most recently held the role of head of IR at Husqvarna Group. He has previously held senior positions at companies such as SCA, Securitas Systems and Elekta. “I am pleased and proud to be joining Saab in the midst of the company's strong growth journey. I look forward to contributing to an open and constructive dialogue with our investors, and to highlighting the company's long-term value...
28.08.25 - 15:03
Elekta AB reports FQ1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.08.25 - 08:57
Elekta Q1 profit jumps 50% as cash flow strengthens despite sales drop (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.25 - 15:48
Novo Nordisks stock plunge isnt surprising. Why companies clear the deck for new CEOs (CNBC)
 
Renault, Elekta, Tietoevry and a number of others have recently reset expectations with investors....
07.07.25 - 13:01
Elekta and Gray partner to offer optimized oncology appointment scheduling for Elekta ONE OIS customers (PR Newswire)
 
MONTRÉAL, July 7, 2025 /PRNewswire/ - Gray Oncology Solutions, Inc. (Gray), a Montréal-based technology company, today announced that it has partnered with Elekta to offer its Care Orchestration Platform, GrayOS, to Elekta ONE OIS customers. Serving as a logistics layer, GrayOS uses an......
01.07.25 - 08:54
Gradientech appoints Veronica Byfield Sköld to Board of Directors (Cision)
 
The diagnostics company Gradientech today announces the appointment of Veronica Byfield Sköld to its Board of Directors, effective May 21, 2025. Following her appointment, the Board now comprises six directors. Veronica Byfield Sköld brings over 25 years of experience in international medtech and life sciences. She has held senior commercial roles at companies including Elekta and Permobil, and served as CEO of the biotech company BioLamina until 2024. Her previous experience also includes positions at Boston Consulting Group (BCG), Gambro, and as Partner at the private equity firm Impilo,...
19.06.25 - 17:12
Fuse Oncology Announces Partnership With Elekta (PR Newswire)
 
Industry vendors team up to support radiation oncology clinics nationwide BOONE, N.C., June 19, 2025 /PRNewswire/ -- Fuse Oncology, an oncology healthcare software solutions provider, today announces its partnership with Elekta, a leading innovator of precision radiation therapy solutions.......
10.06.25 - 13:36
Elekta shares down after SEK 4.9 bln order cancellation; new CEO appointed (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
28.05.25 - 08:54
Elekta AB GAAP EPS of -SEK 1.01, revenue of SEK 5.16B; initiates Q1 outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.05.25 - 08:12
Elekta′s net income plunges 82% in fiscal 2024-25 despite sales growth (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!